Breaking News

Chugai Pharma Appoints CMO

April 25, 2014

Gianella-Borradori brings 20 years of R&D experience

Athos Gianella-Borradori, M.D. has been appointed chief medical officer of Chugai Pharma USA, LLC, a subsidiary of Chugai Pharmaceutical Co. of Tokyo, Japan, and member of the Roche Group.
 
Dr. Gianella-Borradori is pediatric hematologist-oncologist and executive with more than 20 years of international R&D experience focusing on translational research and clinical development of novel therapeutics. He has held senior R&D positions at Novartis, Crucell, Bavarian Nordic, Cyclacel, Merck Serono, and Clavis Pharma. 
 
Dr. Gianella-Borradori is responsible for all clinical activity in the U.S. and will provide leadership for scientific and translational committees in Japan at the parent company. He represents the company in relationships with the FDA, academia, clinical investigators and patient communities, and is responsible for increasing the awareness of Chugai to facilitate its expanding clinical activity in the U.S.
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus